ASCO 2022 Conference Coverage

 

Lung
01:24

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Five-Year Survival Outcomes From CheckMate 227: Nivo + Ipi vs. Chemo as 1L Treatment for mNSCLC

FEATURING Luis Paz-Ares
  • 97 views
  • July 19, 2022
  • 1
10:59

ASCO 2022 Conference Coverage

ASCO 2022 Five-Year Survival Outcomes From CheckMate 227: Nivo + Ipi vs. Chemo as 1L Treatment for mNSCLC

FEATURING Luis Paz-Ares
  • 146 views
  • July 19, 2022
  • 1
01:21

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Phase 3 AcceleRET Lung Study: 1L Pralsetinib in RET Fusion+ Advanced/Metastatic NSCLC

FEATURING Filippo de Marinis
  • 27 views
  • July 14, 2022
12:27

ASCO 2022 Conference Coverage

ASCO 2022 on the Phase 3 AcceleRET Lung Study: 1L Pralsetinib in RET Fusion+ Advanced/Metastatic NSCLC

FEATURING Filippo de Marinis
  • 182 views
  • July 14, 2022
01:08

ASCO 2022 Conference Coverage

Lecture Summary - Pralsetinib in Patients (pts) With Advanced or Metastatic RET-Altered Thyroid Cancer (TC): Updated Data From the ARROW Trial

FEATURING Lori Wirth
  • 20 views
  • July 14, 2022
10:01

ASCO 2022 Conference Coverage

ASCO 2022 Updated Data From the ARROW Trial: Pralsetinib in Patients With Advanced or Metastatic RET-Altered Thyroid Cancer

FEATURING Lori Wirth
  • 158 views
  • July 14, 2022
01:46

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 3-Year Update From CheckMate 9LA: 1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alone (4 cycles) in mNSCLC

FEATURING Luis Paz-Ares
  • 21 views
  • July 13, 2022
09:18

ASCO 2022 Conference Coverage

ASCO 2022 3-Year Update From CheckMate 9LA: 1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alone (4 cycles) in mNSCLC

FEATURING Luis Paz-Ares
  • 477 views
  • July 13, 2022
  • 2
26:58

ASCO 2022 Conference Coverage

ASCO 2022 Immunotherapy Nuances in Locally Advanced NSCLC

FEATURING John Varlotto
  • 31 views
  • July 6, 2022
48

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Immunotherapy Nuances in Locally Advanced NSCLC

FEATURING John Varlotto
  • 23 views
  • July 6, 2022
06:33

ASCO 2022 Conference Coverage

ASCO 2022 on Acquired EGFR-Resistant Mutations in NSCLC

FEATURING Luis Raez
  • 275 views
  • June 30, 2022
  • 3
55

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Acquired EGFR-Resistant Mutations in NSCLC

FEATURING Luis Raez
  • 14 views
  • June 30, 2022
01:06

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Recurrent SCLC: Can We Change the Paradigm?

FEATURING Ryan Gentzler
  • 16 views
  • June 24, 2022
01:28

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Durvalumab +/- Tremelimumab + Chemo in 1L mNSCLC: AE Management in POSEIDON Trial

FEATURING Byoung Chul Cho
  • 14 views
  • June 23, 2022
07:37

ASCO 2022 Conference Coverage

ASCO 2022 on Durvalumab +/- Tremelimumab + Chemo in 1L mNSCLC: AE Management in POSEIDON Trial

FEATURING Byoung Chul Cho
  • 60 views
  • June 23, 2022
05:02

ASCO 2022 Conference Coverage

ASCO 2022 on IO and Chemo-IO for NSCLC With Novel Actionable Oncogenic Driver Alterations

FEATURING Laura Mazzeo, Mario Occhipinti
  • 186 views
  • June 21, 2022
  • 1
01:09

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Impact of Trilaciclib on Multilineage Chemo-Induced Myelosuppression Events in Pts With ES-SCLC: Post-Hoc Analyses of Data From Randomized Clinical Trials

FEATURING Jerome Goldschmidt
  • 18 views
  • June 16, 2022
14:23

ASCO 2022 Conference Coverage

ASCO 2022 Impact of Trilaciclib on Multilineage Chemo-Induced Myelosuppression Events in Pts With ES-SCLC: Post-Hoc Analyses of Data From Randomized Clinical Trials

FEATURING Jerome Goldschmidt
  • 92 views
  • June 16, 2022
  • 1
04:31

ASCO 2022 Conference Coverage

ASCO 2022 Predictors of Biomarker Testing Among Pts With mNSCLC

FEATURING Nicholas Robert
  • 691 views
  • June 16, 2022
  • 2
06:43

ASCO 2022 Conference Coverage

ASCO 2022 on a Phase I, Open-Label, Dose Escalation, Confirmation, and Expansion Trial of BI 1810631 as Monotherapy in Advanced/Metastatic Solid Tumors With HER2 Aberrations

FEATURING John Heymach
  • 106 views
  • June 16, 2022
  • 1
01:17

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on a Phase I, Open-Label, Dose Escalation, Confirmation, and Expansion Trial of BI 1810631 as Monotherapy in Advanced/Metastatic Solid Tumors With HER2 Aberrations

FEATURING John Heymach
  • 14 views
  • June 16, 2022
20:37

Jia Luo

Taking on Goliath: Targeting KRAS in NSCLC

  • 1,195 views
  • June 16, 2022
  • 8
07:03

ASCO 2022 Conference Coverage

ASCO 2022 on Phase 3 ATLANTIS Trial: Analysis of Patients With Relapsed SCLC Receiving Single-Agent Lurbinectedin

FEATURING Alejandro Navarro
  • 253 views
  • June 15, 2022
05:27

ASCO 2022 Conference Coverage

ASCO 2022 on Telisotuzumab Vedotin in Advanced c-Met Overexpressing NSCLC: Monotherapy in Previously Treated Disease; Combination With Osimertinib After Failure on Prior Osi in EGFRm Disease

FEATURING Ross Camidge
  • 180 views
  • June 14, 2022
  • 1
52

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Analysis of Patients With Relapsed SCLC Receiving Single-Agent Lurbinectedin in the Phase 3 ATLANTIS Trial

FEATURING Alejandro Navarro
  • 23 views
  • June 14, 2022
23

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Telisotuzumab Vedotin in Advanced c-Met Overexpressing NSCLC: Monotherapy in Previously Treated Disease; Combination With Osimertinib After Failure on Prior Osi in EGFRm Disease

FEATURING Ross Camidge
  • 289 views
  • June 14, 2022
  • 1
05:57

ASCO 2022 Conference Coverage

ASCO 2022 on TROPION-Lung08: Dato-DXd + Pembro in Treatment-Naïve Advanced/Metastatic NSCLC With PD-L1 ≥ 50% and Without Actionable Genomic Alterations

FEATURING Benjamin Levy
  • 131 views
  • June 10, 2022
  • 2
01:18

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on ctDNA Shed as a Tool to Select Immune CPIs +/- Chemo for aNSCLC

FEATURING Benjamin Besse
  • 88 views
  • June 10, 2022
  • 1
33

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Combi-TED: A Multicenter Phase II Trial Evaluating Efficacy of Tedopi + Docetaxel or Tedopi + Nivo as 2L Therapy in mNSCLC Progressing After 1L Chemo-Immunotherapy

FEATURING Federico Cappuzzo
  • 19 views
  • June 10, 2022
04:36

ASCO 2022 Conference Coverage

ASCO 2022 Combi-TED: A Multicenter Phase II Trial Evaluating Efficacy of Tedopi + Docetaxel or Tedopi + Nivo as 2L Therapy in mNSCLC Progressing After 1L Chemo-Immunotherapy

FEATURING Federico Cappuzzo
  • 64 views
  • June 10, 2022
01:01

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in SCLC and Intracranial Metastatic Disease: A Systematic Review and Meta-Analysis

FEATURING Karolina Gaebe
  • 47 views
  • June 9, 2022
15:49

ASCO 2022 Conference Coverage

ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in SCLC and Intracranial Metastatic Disease: A Systematic Review and Meta-Analysis

FEATURING Karolina Gaebe
  • 431 views
  • June 9, 2022
  • 1
25

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Study of 1L Vibostolimab + Pembro + Etoposide/Platinum vs. Atezo + EP in ES-SCLC

FEATURING Jacob Sands
  • 43 views
  • June 9, 2022
04:05

ASCO 2022 Conference Coverage

ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Study of 1L Vibostolimab + Pembro + Etoposide/Platinum vs. Atezo + EP in ES-SCLC

FEATURING Jacob Sands
  • 510 views
  • June 9, 2022
24

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Clinical and Genomic Characteristics of Pts With Durable Benefit From Immune Checkpoint Inhibitors in Advanced NSCLC

FEATURING Jacob Sands
  • 20 views
  • June 9, 2022
07:37

ASCO 2022 Conference Coverage

ASCO 2022 on Clinical and Genomic Characteristics of Pts With Durable Benefit From Immune Checkpoint Inhibitors in Advanced NSCLC

FEATURING Jacob Sands
  • 278 views
  • June 9, 2022
52

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Three-Year Outcomes and Correlative Analyses in Patients With NSCLC and a Very High PD-L1 Tumor Proportion Score ≥ 90% Treated With 1L Pembrolizumab

FEATURING Biagio Ricciuti
  • 114 views
  • June 8, 2022
07:54

ASCO 2022 Conference Coverage

ASCO 2022 Three-Year Outcomes and Correlative Analyses in Patients With NSCLC and a Very High PD-L1 Tumor Proportion Score ≥ 90% Treated With 1L Pembrolizumab

FEATURING Biagio Ricciuti
  • 319 views
  • June 8, 2022
  • 3
07:00

ASCO 2022 Conference Coverage

ASCO 2022 on GEOMETRY-N Trial: Neoadjuvant and Adjuvant Capmatinib in Resectable NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification

FEATURING Jay Lee
  • 961 views
  • June 8, 2022
  • 4